Wockhardt's Foviscu Matches Meropenem in Phase 3 Trial

Wockhardt's novel antibiotic Foviscu achieved 93.23% clinical cure rate versus 92.31% with meropenem in Phase 3 trial for complicated urinary tract infections, becoming the company's fifth proprietary antibiotic to complete registration-enabling study.

Wockhardt Plans 5-6 New Antibiotics in Next 4-5 Years

Wockhardt chairman announces pipeline of novel antibiotics targeting drug-resistant infections, with Zaynich under USFDA Fast Track review and approval expected by mid-2026.

Wockhardt shares surge 4% on EMA filing for WCK 5222

Wockhardt shares gained nearly 4% after filing marketing authorisation application with European Medicines Agency for novel antibiotic WCK 5222, eligible for accelerated assessment with potential €400-500M market.

Wockhardt Targets European Approval for Zaynich

Wockhardt aims to secure European regulatory approval for its drug Zaynich by July 2026, marking a significant milestone in the pharmaceutical company's international expansion strategy.

Wockhardt Gets Upgraded ESG Rating of 73 (Excellent)

Wockhardt Limited receives improved ESG rating of 73 (Excellent) for 2025 from ESG Risk Assessments & Insights Limited, marking significant improvement from previous 67.3 rating.